




RealRate

PHARMACEUTICAL 2011

Amylin Pharmaceuticals INC
Rank 10 of 31



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Amylin Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Amylin Pharmaceuticals INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 63% points. The greatest weakness of Amylin Pharmaceuticals INC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 328%, being 41% points above the market average of 287%.

Input Variable	Value in 1000 USD
Assets, Current	676,395
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	401,595
Liabilities, Non-Current	0
Other Assets	43,289
Other Compr. Net Income	0
Other Expenses	363,862
Other Liabilities	0
Other Net Income	0
Other Revenues	671,511
Property and Equipment	811,745
Research and Development	171,312
Selling, General and Administrative Expense	288,650

Output Variable	Value in 1000 USD
Assets	1,531,429
Liabilities	401,595
Expenses	823,824
Revenues	671,511
Stockholders Equity	1,129,834
Net Income	-152,313
Comprehensive Net Income	-152,313
BaseVar	1,714,180
ECR before LimitedLiability	239%
Economic Capital Ratio	328%